Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | MYH9 | P35579 | 1/20 | 1.00 |
| ▸ | MYH10 | P35580 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | MYH2 | Q9UKX2 | 1/20 | 0.62 |
| ▸ | METAP2 | P50579 | 8/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330341 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL4330339 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL29354793 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL30075966 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL15919292 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL23909200 | 0.92 | MEN1 (0.85) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL23235584 | 0.92 | MEN1 (0.85) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL21067621 | 0.91 | MEN1 (0.83) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL23909209 | 0.90 | MEN1 (0.82) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL23909208 | 0.90 | MEN1 (0.82) | MEN1KMT2AMAPTKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118931833-A | Method for obtaining platelets by inducing iPSC differentiation | 呈诺再生医学科技(北京)有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-115873797-B | Amplification culture medium and culture method for retinal pigment epithelial cells | 北京干细胞与再生医学研究院 | 2024-08-13 | — | — | CN | claimed |
| US-11622964-B2 | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof | INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-04-11 | — | — | US | claimed |
| CN-111778205-B | Human cardiac muscle cell separation reagent, culture medium, separation method and culture method | 青岛百洋智心科技有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-111405898-B | Method for destroying cell mechanical homeostasis and promoting tissue and organ regeneration and repair and application thereof | 中国科学院动物研究所 | 2022-09-13 | — | — | CN | claimed |
| CN-114807034-A | Preparation method of Muller cells derived from human pluripotent stem cells | 中山大学中山眼科中心 | 2022-07-29 | — | — | CN | claimed |
| CN-113234670-B | Separation and culture method of adult mouse atrial myocytes | 西安交通大学 | 2022-07-12 | — | — | CN | claimed |
| US-20220213444-A1 | COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING | CHILDRENS HOSPITAL MED CT (US) | 2022-07-07 | — | — | US | claimed |
| CN-114369572-A | Composition and method for transdifferentiating non-neuronal cells into neurons | 中国科学院动物研究所 | 2022-04-19 | — | — | CN | claimed |
| EP-3976767-A1 | COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING | Children's Hospital Medical Center, Center for Technology Commercialization (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114207119-A | Compositions and methods for reprogramming of cells | 儿童医院医学中心 | 2022-03-18 | — | — | CN | claimed |
| US-20250341512-A1 | HIGH-THROUGHPUT AUTOMATION OF ORGANOIDS FOR IDENTIFYING THERAPEUTIC STRATEGIES | UNIVERSITY OF WASHINGTON (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333708-A1 | MANIPULATING NEPHRON DIFFERENTIATION RATE IN INDUCED HUMAN PLURIPOTENT STEM CELL ORGANOIDS AND TISSUES BY ENGINEERING MECHANICS OF THE MICROENVIRONMENT | UNIV PENNSYLVANIA (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4627085-A1 | LONG NON-CODING RNA LIPTER PRESERVES LIPID METABOLISM OF THE HUMAN HEART | The Trustees of Indiana University (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12421243-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) | 2025-09-23 | — | — | US | disclosed |
| CN-114369572-A | Composition and method for transdifferentiating non-neuronal cells into neurons | 中国科学院动物研究所 | 2022-04-19 | — | — | CN | disclosed |
| EP-3976767-A1 | COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING | Children's Hospital Medical Center, Center for Technology Commercialization (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114207119-A | Compositions and methods for reprogramming of cells | 儿童医院医学中心 | 2022-03-18 | — | — | CN | disclosed |
| EP-3967751-A1 | HUMAN CARDIOMYOCYTE SEPARATION REAGENT, CULTURE MEDIUM, SEPARATION METHOD, AND CULTURE METHOD | Fuwai Hospital of Chinese Academy of Medical Sciences (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022037570-A1 | EXPANSION CULTURE MEDIUM AND CULTURE METHOD FOR NEURAL CELLS | 中国科学院动物研究所 | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622964-B2 | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof | MYLK2, MYLK, MYLK3 | MEN1 2498/4885KMT2A 3509/4885MAPT 4727/4885 |
| US-12421243-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | MEN1 2122/4885KMT2A 3113/4885MAPT 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.